Catalyst Brief

← Calendar

Readoutin 135d

Bayer — Finerenone (Kerendia, BAY94-8862)

Phase 3 primary completion: A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria.

Date
Apr 2027
Type
Readout
Indication
Chronic Kidney Disease

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.